Vor Biopharma Inc. Common Stock
VORVor Biopharma Inc. (VOR) is a biotechnology company focused on developing targeted therapies for cancer using cell engineering technologies. The company aims to create treatments that selectively eliminate cancer cells while preserving healthy cells, leveraging its proprietary gene-editing platforms. Founded to address challenges in oncology, Vor Biopharma emphasizes precision medicine approaches to improve patient outcomes.
Company News
Vor Bio announced on July 1, 2026, that it granted stock options to purchase 71,200 shares and RSUs representing 15,150 shares to 7 newly hired employees as material inducements to employment. The options have a 10-year term with an exercise price of $18.39 per share and vest over four years, with RSUs vesting quarterly over the same period.
Vor Bio announced the grant of stock options to purchase 61,050 shares and RSUs representing 12,900 shares to 10 newly hired employees on June 1, 2026. The stock options have a 10-year term with an exercise price of $14.57 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The RSUs also vest over fou...
Vor Bio announced the grant of stock options to purchase 42,650 shares and RSUs representing 9,050 shares to 9 newly hired employees on April 1, 2026. The stock options have a 10-year term with an exercise price of $17.39 per share and vest over four years, with 25% vesting after 12 months followed by monthly vesting. The grants were made as mate...
Vor Biopharma is conducting a public offering of 10 million shares at $10 per share, expecting to raise $100 million. The offering includes an option for underwriters to purchase an additional 1.5 million shares.
Telitacicept demonstrated a 55% reduction in proteinuria and statistically significant improvements in kidney function during a Phase 3 clinical trial for IgA Nephropathy in China, with a favorable safety profile.
